Your session is about to expire
← Back to Search
Mineral Supplement
Magnesium Supplementation for High Blood Pressure
N/A
Recruiting
Research Sponsored by Brigham and Women's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Total magnesium intake from supplements of no more than 100 mg/day
Be older than 18 years old
Must not have
History of renal disease
History of kidney failure
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Summary
This trial is testing if taking a daily magnesium supplement for a few months can lower blood pressure in adults aged 30-74 with slightly high blood pressure. Magnesium helps relax blood vessels, which may help reduce blood pressure. Magnesium supplementation has been studied for over 25 years with inconsistent results in lowering blood pressure.
Who is the study for?
This trial is for adults with a self-reported systolic blood pressure between 125-159 mmHg and measured seated systolic blood pressure of 130-159 mmHg. Participants should have a BMI under 40, take no more than 100 mg/day of magnesium from supplements, and be willing to keep their diet the same during the study. People with severe high blood pressure, certain chronic diseases, or those who are pregnant or planning to move away can't join.
What is being tested?
The trial is testing if taking a daily dose of magnesium glycinate (480 mg) for three months can lower high systolic blood pressure compared to a placebo. The participants will either receive the supplement or an inactive pill without knowing which one they're getting.
What are the potential side effects?
Magnesium supplements may cause digestive issues like diarrhea or stomach cramps in some people. High doses might lead to more serious problems such as irregular heartbeat but this is rare especially at controlled doses.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I take 100 mg or less of magnesium supplements daily.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have a history of kidney disease.
Select...
I have had kidney failure in the past.
Select...
I have used antacids or laxatives 4 or more times a week in the last 3 months.
Select...
I have been on dialysis.
Select...
I cannot or do not want to swallow 4 pills daily.
Select...
I have a history of heart disease, including heart attack, stroke, or procedures to improve blood flow to my heart.
Select...
I have a history of inflammatory bowel disease.
Select...
I am not pregnant, nursing, or planning to become pregnant during treatment.
Select...
I have a history of diabetes (type 1 or 2).
Select...
I have had pancreatitis before.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Trial Design
2Treatment groups
Active Control
Placebo Group
Group I: magnesiumActive Control1 Intervention
magnesium glycinate supplement, 480 mg/day
Group II: placeboPlacebo Group1 Intervention
placebo supplement
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for high blood pressure include ACE inhibitors and ARBs, which relax blood vessels by inhibiting the renin-angiotensin system; calcium channel blockers, which prevent calcium from entering heart and blood vessel cells, leading to relaxed vessels; diuretics, which reduce blood volume by increasing urine output; and beta-blockers, which decrease heart rate and output. Magnesium supplementation, like magnesium glycinate, improves vascular tone and function, potentially lowering blood pressure by relaxing blood vessels and enhancing endothelial function.
These mechanisms are crucial for managing high blood pressure as they help reduce the risk of cardiovascular events and organ damage.
Targeting Ouabain- and Adducin-dependent mechanisms of hypertension and cardiovascular remodeling as a novel pharmacological approach.Management of life-threatening autonomic hyper-reflexia using magnesium sulphate in a patient with a high spinal cord injury in the intensive care unit.
Targeting Ouabain- and Adducin-dependent mechanisms of hypertension and cardiovascular remodeling as a novel pharmacological approach.Management of life-threatening autonomic hyper-reflexia using magnesium sulphate in a patient with a high spinal cord injury in the intensive care unit.
Find a Location
Who is running the clinical trial?
Brigham and Women's HospitalLead Sponsor
1,669 Previous Clinical Trials
11,877,696 Total Patients Enrolled
Pure EncapsulationsIndustry Sponsor
1 Previous Clinical Trials
59 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have not had any cancer, except for non-melanoma skin cancer, in the last 5 years.I have a history of kidney disease.I have had kidney failure in the past.I have used antacids or laxatives 4 or more times a week in the last 3 months.Your blood pressure is between 130 and 159 when you are sitting down.I have been on dialysis.I cannot or do not want to swallow 4 pills daily.I have a history of heart disease, including heart attack, stroke, or procedures to improve blood flow to my heart.You have a systolic blood pressure reading between 125 and 159 mmHg when you measure it yourself.Your blood pressure is 100 mmHg or higher when measured while sitting down.I have a history of inflammatory bowel disease.You have a history of having too much magnesium in your blood.I am not pregnant, nursing, or planning to become pregnant during treatment.I have a history of diabetes (type 1 or 2).Your body mass index (BMI) is less than 40.I have had pancreatitis before.I take 100 mg or less of magnesium supplements daily.
Research Study Groups:
This trial has the following groups:- Group 1: magnesium
- Group 2: placebo
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.